The forecasted mortality rate for cervix uteri malignant neoplasms in the US remains stable at 2.4 deaths per hundred thousand women from 2024 to 2027, with a slight decrease to 2.3 in 2028. In 2023, the rate was at 2.4, indicating no change in the immediate following years. The absence of year-on-year variation from 2024 to 2027 demonstrates steadiness, while the slight dip in 2028 suggests a marginal improvement. The compound annual growth rate over the next five years reveals no significant deviation, portraying a stable outlook.
Future trends to watch for include advancements in cervical cancer screening and vaccination which could further decrease mortality rates. Monitoring health policy changes and access to healthcare services can provide additional insights into potential improvements or declines in these rates.
